Evidence map›Paper›PMID 33926203›Full record

ArticleCirculation2021

Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016.

Maxwell Birger, Alexander S Kaldjian, Gregory A Roth, Andrew E Moran, Joseph L Dieleman, Brandon K Bellows

Open access · bronzeAbstract readHistorical Article
In one paragraph

Article in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
30.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Cellular and molecular mechanisms underlying cardiovascular aging.Cellular & molecular biology letters · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Maxwell BirgerColumbia University Irving Medical Center, New York (M.B., A.E.M., B.K.B.).
Alexander S KaldjianInstitute for Health Metrics and Evaluation, Seattle, WA (A.S.K., G.A.R., J.L.D.).
Gregory A RothUniversity of Washington, Seattle (M.B., G.A.R.).
Andrew E MoranColumbia University Irving Medical Center, New York (M.B., A.E.M., B.K.B.).
Joseph L DielemanInstitute for Health Metrics and Evaluation, Seattle, WA (A.S.K., G.A.R., J.L.D.).
Brandon K BellowsColumbia University Irving Medical Center, New York (M.B., A.E.M., B.K.B.).
Columbia University Irving Medical Center · USInstitute for Health Metrics and Evaluation · USUniversity of Washington · US

Funding

Comparing the value of intensive systolic blood pressure treatment implementation strategiesK01HL140170 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BELLOWS, BRANDON K · 2018 to 2022
$709k
NHLBI NIH HHS K01 HL140170
6 · The paper itself

Abstract

backgroundSpending on cardiovascular disease and cardiovascular risk factors (cardiovascular spending) accounts for a significant portion of overall US health care spending. Our objective was to describe US adult cardiovascular spending patterns in 2016, changes from 1996 to 2016, and factors associated with changes over time.

methodsWe extracted information on adult cardiovascular spending from the Institute for Health Metrics and Evaluation's disease expenditure project, which combines data on insurance claims, emergency department and ambulatory care visits, inpatient and nursing care facility stays, and drug prescriptions to estimate >85% of all US health care spending. Cardiovascular spending (2016 US dollars) was stratified by age, sex, type of care, payer, and cardiovascular cause. Time trend and decomposition analyses quantified contributions of epidemiology, service price and intensity (spending per unit of utilization, eg, spending per inpatient bed-day), and population growth and aging to the increase in cardiovascular spending from 1996 to 2016.

resultsAdult cardiovascular spending increased from $212 billion in 1996 to $320 billion in 2016, a period when the US population increased by >52 million people, and median age increased from 33.2 to 36.9 years. Over this period, public insurance was responsible for the majority of cardiovascular spending (54%), followed by private insurance (37%) and out-of-pocket spending (9%). Health services for ischemic heart disease ($80 billion) and hypertension ($71 billion) led to the most spending in 2016. Increased spending between 1996 and 2016 was primarily driven by treatment of hypertension, hyperlipidemia, and atrial fibrillation/flutter, for which spending rose by $42 billion, $18 billion, and $16 billion, respectively. Increasing service price and intensity alone were associated with a 51%, or $88 billion, cardiovascular spending increase from 1996 to 2016, whereas changes in disease prevalence were associated with a 37%, or $36 billion, spending reduction over the same period, after taking into account population growth and population aging.

conclusionsUS adult cardiovascular spending increased by >$100 billion from 1996 to 2016. Policies tailored to control service price and intensity and preferentially reimburse higher quality care could help counteract future spending increases caused by population aging and growth.

Indexed as

Ambulatory CareCardiovascular DiseasesDrug CostsFactor Analysis, StatisticalHealth Care CostsHealth ExpendituresHeart Disease Risk FactorsHistory, 20th CenturyHistory, 21st CenturyHumansInsurance, HealthPublic Health SurveillanceUnited Statescardiovasculardiseasehealth economicshealth expenditures

Identifiers

PMID33926203
PMCPMC8316421
OpenAlexW3158582476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.